Document is current
Any future updates will be listed below
-
Authors
Louie, Raymond Hall Yip
Cai, Curtis http://orcid.org/0000-0002-3490-4361
Samir, Jerome
Singh, Mandeep http://orcid.org/0000-0002-6998-3805
Deveson, Ira W. http://orcid.org/0000-0003-3861-0472
Ferguson, James M. http://orcid.org/0000-0002-6192-6937
Amos, Timothy G. http://orcid.org/0000-0002-5829-6655
McGuire, Helen Marie
Gowrishankar, Kavitha
Adikari, Thiruni
Balderas, Robert http://orcid.org/0000-0002-8734-8629
Bonomi, Martina
Ruella, Marco http://orcid.org/0000-0003-4301-5811
Bishop, David http://orcid.org/0000-0001-6415-1455
Gottlieb, David
Blyth, Emily http://orcid.org/0000-0002-7849-7139
Micklethwaite, Kenneth
Luciani, Fabio http://orcid.org/0000-0003-0666-6324
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1128416, 1102172, 1121704, 1121643)
- License Information
-
More Information
Article History
Received: 26 September 2023
Accepted: 15 November 2023
First Online: 27 November 2023
Competing interests
: F.L. has received funding from BD Bioscience to perform part of the experiments reported in this study. E.B., D.G., and K.M. hold patents in adoptive cell therapy for opportunistic infection and malignancy. E.B. advisory roles for Abbvie, Astellas, MSD, Novartis, BMS and Bastion Education. E.B. receives research funding from MSD unrelated to the work described in this manuscript. R.B. is an employee of Becton Dickinson and helped with the implementation of the Rhapsody and AbSeq technology. M.R. holds patents related to CD19 CAR T cells which are licensed to Novartis, Tmunity (Kite-Gilead), and viTToria Biotherapeutics. M.R. has served as a consultant for NanoString, BMS, GSK, GLG, Sana, Bayer, Guidepoint, Scailyte, and AbClon. M.R. receives research funding from AbClon, Beckman Coulter, CurioX, Oxoford Nano Imaging, and viTToria Biotherapeutics. M.R. is the scientific founder of viTToria biotherapeutics. J.M.F. and I.W.D. have received travel and accommodation expenses from Oxford Nanopore Technologies. The remaining authors declare no competing interests.
